文献速递头痛与眩晕

降钙素基因相关肽输注对丛集性头痛发作的影响:一项随机临床试验

Effect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2018-01-01

这项随机双盲安慰剂对照交叉研究在丹麦头痛中心纳入32例丛集性头痛患者,比较静脉输注降钙素基因相关肽(CGRP)1.5 μg/min与安慰剂20分钟对丛集性头痛样发作的影响。CGRP在发作期发作性丛集性头痛和慢性丛集性头痛中诱发发作,但在缓解期发作性丛集性头痛中未诱发发作,提示抗CGRP药物可能对丛集性头痛治疗有效。

要点

  • CGRP输注在发作期发作性丛集性头痛患者中诱发发作的比例为89%(8/9),安慰剂组为11%(1/9),P=0.05。
  • CGRP输注在慢性丛集性头痛患者中诱发发作的比例为50%(7/14),安慰剂组为0/14,P=0.02。
  • 缓解期发作性丛集性头痛患者中,CGRP和安慰剂均未诱发发作。

核心结论

  • CGRP在发作期发作性丛集性头痛和慢性丛集性头痛中诱发丛集性头痛发作,但在缓解期发作性丛集性头痛中不诱发发作。
  • 这些结果提示抗CGRP药物可能对丛集性头痛管理有效。

研究设计与样本

  • 随机、双盲、安慰剂对照、二阶段交叉研究,设在丹麦Rigshospitalet Glostrup的丹麦头痛中心,分析采用意向性治疗。
  • 纳入标准为发作性或慢性丛集性头痛诊断、年龄18至65岁、女性采取安全避孕;排除标准为其他原发性头痛史(除每月少于5天的发作性紧张型头痛)、妊娠或哺乳、心血管、脑血管或精神疾病、药物滥用。
  • 2015年12月至2017年4月纳入37例丛集性头痛患者,在2个研究日接受静脉输注1.5 μg/min的CGRP或安慰剂20分钟。
  • 评估91例患者资格,32例(35.2%)纳入分析;平均(标准差)年龄36(10.7)岁(范围19-60岁),平均体重78 kg(范围53-100 kg),27名男性(84.4%)完成研究。

主要发现

  • 发作期发作性丛集性头痛患者中,CGRP诱发发作8/9例(均值89%;95%CI 63-100),安慰剂组1/9例(均值11%;95%CI 0-37),P=0.05。
  • 缓解期发作性丛集性头痛患者中,CGRP或安慰剂后均无患者报告发作。
  • 慢性丛集性头痛患者中,CGRP诱发发作7/14例(均值50%;95%CI 20-80),安慰剂后无发作(P=0.02)。
  • 发作期发作性丛集性头痛患者中,0至90分钟头痛强度评分曲线下面积(AUC)均值CGRP组为1.903(95%CI 0.842-2.965),安慰剂组为0.343(95%CI 0-0.867),P=0.04。
  • 慢性丛集性头痛患者中,0至90分钟AUC均值CGRP组为1.214(95%CI 0.395-2.033),安慰剂组为0.036(95%CI 0-0.114),P=0.01;缓解期发作性丛集性头痛患者中,CGRP组为0.187(95%CI 0-0.571),安慰剂组为0.019(95%CI 0-0.062),P>0.99。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Signaling molecule calcitonin gene-related peptide (CGRP) induces migraine attacks and anti-CGRP medications abort and prevent migraine attacks. Whether CGRP provokes cluster headache attacks is unknown. OBJECTIVE: To determine whether CGRP induces cluster headache attacks in episodic cluster headache in active phase, episodic cluster headache in remission phase, and chronic cluster headache. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled, 2-way crossover study set at the Danish Headache Center, Rigshospitalet Glostrup, in Denmark. Analyses were intent to treat. Inclusion took place from December 2015 to April 2017. Inclusion criteria were diagnosis of episodic/chronic cluster headache, patients aged 18 to 65 years, and safe contraception in women. Exclusion criteria were a history of other primary headache (except episodic tension-type headache <5 days/mo), individuals who were pregnant or nursing; cardiovascular, cerebrovascular, or psychiatric disease; and drug misuse. INTERVENTIONS: Thirty-seven patients with cluster headaches received intravenous infusion of 1.5 μg/min of CGRP or placebo over 20 minutes on 2 study days. MAIN OUTCOMES AND MEASURES: Difference in incidence of cluster headache-like attacks, difference in area under the curve (AUC) for headache intensity scores (0 to 90 minutes), and difference in time to peak headache between CGRP and placebo in the 3 groups. RESULTS: Of 91 patients assessed for eligibility, 32 patients (35.2%) were included in the analysis. The mean (SD) age was 36 (10.7) years (range, 19-60 years), and the mean weight was 78 kg (range, 53-100 kg). Twenty-seven men (84.4%) completed the study. Calcitonin gene-related peptide induced cluster headache attacks in 8 of 9 patients in the active phase (mean, 89%; 95% CI, 63-100) compared with 1 of 9 in the placebo group (mean, 11%; 95% CI, 0-37) (P = .05). In the remission phase, no patients with episodic cluster headaches reported attacks after CGRP or placebo. Calcitonin gene-related peptide-induced attacks occurred in 7 of 14 patients with chronic cluster headaches (mean, 50%; 95% CI, 20-80) compared with none after placebo (P = .02). In patients with episodic active phase, the mean AUC from 0 to 90 minutes for CGRP was 1.903 (95% CI, 0.842-2.965), and the mean AUC from 0 to 90 minutes for the placebo group was 0.343 (95% CI, 0-0.867) (P = .04). In patients with chronic cluster headache, the mean AUC from 0 to 90 minutes for CGRP was 1.214 (95% CI, 0.395-2.033), and the mean AUC from 0 to 90 minutes for the placebo group was 0.036 (95% CI, 0-0.114) (P = .01). In the remission phase, the mean AUC from 0 to 90 minutes for CGRP was 0.187 (95% CI, 0-0.571), and the mean AUC from 0 to 90 minutes for placebo was 0.019 (95% CI, 0-0.062) (P > .99). CONCLUSIONS AND RELEVANCE: Calcitonin gene-related peptide provokes cluster headache attacks in active-phase episodic cluster headache and chronic cluster headache but not in remission-phase episodic cluster headache. These results suggest anti-CGRP drugs may be effective in cluster headache management. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02466334).

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Vollesen ALH, Snoer A, Beske RP, et al. Effect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks: A Randomized Clinical Trial. JAMA Neurol. 2018. PMID: 29987329. doi:10.1001/jamaneurol.2018.1675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。